Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
2003 |
| gptkbp:ATCCode |
N06DX01
|
| gptkbp:brand |
gptkb:Namenda
gptkb:Akatinol gptkb:Ebixa |
| gptkbp:CASNumber |
41100-52-1
|
| gptkbp:chemicalFormula |
C12H21N
|
| gptkbp:contraindication |
hypersensitivity to memantine
|
| gptkbp:drugClass |
NMDA receptor antagonist
|
| gptkbp:eliminationHalfLife |
60-80 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:genericName |
gptkb:memantine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Namenda
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Allergan
|
| gptkbp:mechanismOfAction |
NMDA receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:prescribes |
moderate to severe Alzheimer's disease
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
confusion
constipation dizziness headache |
| gptkbp:usedFor |
gptkb:Alzheimer's_disease
|
| gptkbp:bfsParent |
gptkb:memantine
|
| gptkbp:bfsLayer |
5
|